Alzheimer's disease: A hypothesis on pathogenesis

Journal of the American Aging Association

Volumn 23, Issue 3, 2000, Pages 147-161

  Harman, D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; CALCIUM ION; PRESENILIN 1; PRESENILIN 2; SUPEROXIDE;

AGING; ALZHEIMER DISEASE; ARTICLE; CALCIUM CELL LEVEL; CELL LOSS; DIET; DOWN SYNDROME; ENDOPLASMIC RETICULUM; FAMILIAL DISEASE; FEMALE; GENE MUTATION; HUMAN; HYPOTHESIS; MALE; MITOCHONDRION; MORTALITY; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; ONSET AGE; PATHOGENESIS; PROTEIN DEGRADATION; SENILE PLAQUE;

EID: 0033773121     PISSN: 01619152     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11357-000-0017-6     Document Type: Article

References (155)

1. Alzheimer's disease
2. Risky apolipoprotein in brain
3. Genetic factors in Alzheimer's disease
4. Age-dependent expression of familial risk in Alzheimer's disease
5. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14
6. A familial Alzheimer's disease locus on chromosome 1
7. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
8. Advances in Alzheimer's disease
9. Systemic manifestations of Alzheimer's disease
10. Alzheimer disease: Basic and clinical advances
11. Neuritic pathology and dementia in Alzheimer's disease
12. Ultrastructural alterations in senile dementia
13. Structural basis of the cognitive alterations
14. Free radical theory of aging: Alzheimer's disease pathogenesis
15. Noncognitive symptoms of Alzheimer's disease
16. Clinical presentation, diagnosis, and symptomatology of age-associated cognitive decline and Alzheimer's disease
17. Diagnosis
18. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome
19. Clinicopathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease
20. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease
21. Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer's donors
22. Evidence for a membrane defect in Alzheimer's disease brain
23. Alzheimer's disease and cellular aging: Membrane-related events as clues to primary mechanisms
24. Cytochrome oxidase deficiency in Alzheimer's disease
25. Epidemiology of Alzheimer's disease
26. Editorial: Amyloid and Alzheimer's disease
27. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease
28. Translating cell biology into therapeutic advances in Alzheimer's disease
29. Mechanisms of neuronal degeneration in Alzheimer's disease
30. Alzheimer's disease: The amyloid cascade hypothesis
31. New clues to Alzheimer's disease: Unraveling the roles of amyloid and tau
32. Alzheimer's disease: Genotypes, phenotypes, and treatments
33. The pathogenesis of senile plaques
34. Amyloidogenicity of βA4 and βA4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation
35. The pathogenesis of Alzheimer disease: An alternative to the amyloid hypothesis
36. The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex
37. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
38. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity
39. γ-Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid β peptides of varying length
40. Presenilins: Molecular switches between proteolysis and signal transduction
41. Presenilin 1 controls γ-secretase processing of amyloid precursor protein in pre-Golgi compartments of hippocampal neurons
42. The transmembrane aspartates in presenilin 1 and 2 are obligatory for γ-secretase activity and amyloid β-protein generation
43. Calcium ionophore increases amyloid β peptide production by cultured cells
44. Mechanism and prevention of neurotoxicity caused by β-amyloid peptides: Relation to Alzheimer's disease
45. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease
46. Superoxide mediates the cell-death-enhancing action of presenilin-1 mutations
47. Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: Involvement of perturbed calcium homeostasis
48. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases
49. Glial cytokines in Alzheimer's disease: Review and pathogenic implications
50. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease
51. Interleukin (IL) 1 β, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: Pathophysiological implications
52. Inflammation and Alzheimer's disease: Relationships between pathogenic mechanisms and clinical expression
53. Neuroinflammatory processes are important in neurodegenerative diseases: An hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development
54. Seeding of Aβ fibril formation is inhibited by all three isotopes of apolipoprotein E
55. Amyloid fibril formation by an SH3 domain
56. Oxidative stress and Alzheimer disease
57. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease
58. Free radical theory of aging: A hypothesis on pathogenesis of senile dementia of the Alzheimer's type
59. Aging: Phenomena and theories
60. Aging: Prospects for further increases in the functional life span
61. The relation of human health to age, place and time
62. Befolknings forandringar
63. Aging: A theory based on free radical and radiation chemistry
64. The biologic clock: The mitochondria?
65. Free radical theory of aging: Consequences of mitochondrial aging
66. Free radical theory of aging: The 'free radical' diseases
67. 1 mice
68. Effect of ethoxyquin on the longevity of C3H mice
69. Free radical theory of aging: Beneficial effects of adding antioxidants to the maternal mouse diet on life span of offspring: Possible explanation of the sex difference in longevity
70. Studies of mitochondrial development during embryogenesis in the rat
71. Studies of mitochondria in oxidative embryotoxicity
72. High oestrogen excretion in pregnancy
73. Genotoxic effects of estrogens
74. Protective effect of vitamin E on fetal distress induced by ischemia of the uteroplacental system in pregnant rats
75. Ischemia/reperfusion: A new hypothesis for the developmental toxicity of cocaine
76. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
77. Does superoxide underlie the pathogenesis of hypertension?
78. Aging: Minimizing free radical damage
79. Birth weight and adult hypertension, diabetes mellitus, and obesity in US men
80. Is the 'preamyloid' of diffuse plaques in Alzheimer's disease really nonfibrillar?
81. Hydrogen peroxide release by mitochondria increases during aging
82. 2 consumption can explain the simultaneous presence of high longevity and high aerobic metabolic rate in birds
83. Oxidative stress up-regulates IL-8 and TNF-α synthesis by human dendritic cells
84. Inflammation, Aβ deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration
85. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1
86. Binding of human apolipoprotein E to synthetic amyloid β peptide: Isoform-specific effects and implications for late-onset Alzheimer's disease
87. Revolution in mitochondrial medicine
88. Mitochondrial involvement in Alzheimer's disease
89. Mitochondrial DNA sequence analysis of four Alzheimer's and Parkinson's disease patients
90. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer's disease
91. Oxidative phosphorylation diseases: Disorders of two genomes
92. Mitochondrial genetics: A paradigm for aging and degenerative diseases?
93. Mitochondrial myopathies: Clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA
94. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome
95. Amyloid, the presenilins and Alzheimer's disease
96. Identification, biogenesis and location of precursors of Alzheimer's disease A4 amyloid protein
97. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains β-catenin
98. The influence of endoproteolytic processing of familial Alzheimer's disease presenilin 2 on Aβ42 amyloid peptide formation
99. Autophagy, micro-autophagy and crinophagy as mechanisms for protein degradation
100. Structure of the calcium pump from sarcoplasmic reticulum at 8-Å resolution
101. +-ATPase in the open conformation
102. 2+-ATPases
103. 2+ homeostasis
104. Inositol phosphates and cell signalling
105. Inhibition of the skeletal muscle ryanodine receptor calcium channel by nitric oxide
106. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation
107. 2+-ATPase through intramembrane interactions
108. 2+-ATPase by phospholamban
109. Sites on the cytoplasmic region of phospolamban involved in interaction with calcium-activated ATPase of the sarcoplasmic reticulum
110. 2+-ATPase
111. 2+-ATPase
112. 2+-ATPase
113. Alteration of acylphosphatase levels in familia Alzheimer's disease fibroblasts with presenilin gene mutations
114. Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: Reduced oxidative stress and preserved mitochondrial function
115. Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid β-peptide toxicity: Central roles of superoxide production and caspase activation
116. Oxidants in mitochondria: From physiology to diseases
117. Down's syndrome and Alzheimer's disease: A review
118. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease
119. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years with Down's syndrome
120. Aging and Alzheimer's disease in people with Down's syndrome
121. Trisomy 21 (Down's syndrome): Glutathione peroxidase, hexose monophosphate shunt and I.Q.
122. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro
123. The association between head trauma and Alzheimer's disease
124. The occult aftermath of boxing
125. Neurological sequelae of boxing
126. βA4 Amyloid protein deposition in brain after head trauma
127. The cerebral vasculature in dementia pugilistica
128. Hydrogen peroxide mediates amyloid β protein toxicity
129. Abnormalities of the electron transport chain in idiopathic Parkinson's disease
130. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease
131. Mitochondrial Complex I deficiency in Parkinson's disease
132. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease
133. Ultrastruture of skeletal muscle in patients with Parkinson's disease and upper motor lesions
134. Parkinson's disease: Pathophysiology
135. Cognitive impairement in Parkinson's disease: Amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex
136. Diffuse Lewy body disease: An important differential diagnosis in dementia with extrapyramidal features
137. Prospects for pharmacological intervention in Alzheimer disease
138. Free radical theory of aging: Increasing the average life expectancy at birth and the maximum life span
139. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
140. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters
141. Propofol hemisuccinate protects neuronal cells from oxidative injury
142. The elusive function of metallothioneins
143. Enhanced neurothrophic activity in Alzheimer's disease cortex is not associated with down-regulation of metallothionein-III (GIF)
144. NADH-CoQ reductase deficient myopathy: Successful treatment with riboflavin
145. 3 and C in a patient with a defect in electron transport at complex III in skeletal muscle
146. 10
147. Clinical trial of indomethacin in Alzheimer's disease
148. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study
149. Inflammation and Alzheimer's disease pathogenesis
150. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
151. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
152. A substrate-based difluoro ketone selectively inhibits Alzheimer's γ-secretase activity
153. Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation